An Open Label, Single Arm, Multicentre Study to Assess the Clinical Efficacy and Safety of Lynparza (Olaparib) Tablets Maintenance Monotherapy in Platinum Sensitive Relapsed Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (L-MOCA)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Olaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms L-MOCA
- Sponsors AstraZeneca
- 08 Nov 2019 Planned number of patients changed from 300 to 360.
- 08 Nov 2019 Planned End Date changed from 1 Mar 2022 to 21 Dec 2021.
- 08 Nov 2019 Planned primary completion date changed from 1 Mar 2022 to 21 Dec 2021.